{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T14:42:25Z","timestamp":1770734545738,"version":"3.49.0"},"publisher-location":"Berlin, Heidelberg","reference-count":245,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642257605","type":"print"},{"value":"9783642257612","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012]]},"DOI":"10.1007\/978-3-642-25761-2_4","type":"book-chapter","created":{"date-parts":[[2012,11,5]],"date-time":"2012-11-05T12:42:29Z","timestamp":1352119349000},"page":"87-124","source":"Crossref","is-referenced-by-count":86,"title":["Serotonergic Mechanisms as Targets for Existing and Novel Antipsychotics"],"prefix":"10.1007","author":[{"given":"Herbert Y.","family":"Meltzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,28]]},"reference":[{"issue":"1","key":"4_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","volume":"205","author":"AI Abbas","year":"2009","unstructured":"Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL (2009) Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 205(1):119\u2013128","journal-title":"Psychopharmacology (Berl)"},{"issue":"12","key":"4_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.biopsych.2008.12.007","volume":"65","author":"A Abi-Dargham","year":"2009","unstructured":"Abi-Dargham A, Van de Giessen E, Slifstein M, Kegeles LS, Laruelle M (2009) Baseline and amphetamine-stimulated dopamine activity are related in drug-na\u00efve schizophrenic subjects. Biol Psychiatry 65(12):1091\u20131093","journal-title":"Biol Psychiatry"},{"issue":"4\u20135","key":"4_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0028-3908(97)00051-8","volume":"36","author":"GK Aghajanian","year":"1997","unstructured":"Aghajanian GK, Marek GJ (1997) Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36(4\u20135):589\u2013599","journal-title":"Neuropharmacology"},{"issue":"4","key":"4_CR4","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.neuropharm.2011.05.023","volume":"61","author":"L Albizu","year":"2011","unstructured":"Albizu L, Holloway T, Gonz\u00e1lez-Maeso J, Sealfon SC (2011) Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors. Neuropharmacology 61(4):770\u2013777","journal-title":"Neuropharmacology"},{"issue":"4","key":"4_CR5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/0361-9230(86)90181-4","volume":"16","author":"CA Altar","year":"1986","unstructured":"Altar CA, Wasley AM, Neale RF, Stone GA (1986) Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Res Bull 16(4):517\u2013525","journal-title":"Brain Res Bull"},{"issue":"3","key":"4_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.neuropharm.2011.01.015","volume":"61","author":"R Andrade","year":"2011","unstructured":"Andrade R (2011) Serotonergic regulation of neuronal excitability in the prefrontal cortex. Neuropharmacology 61(3):382\u2013386","journal-title":"Neuropharmacology"},{"issue":"1","key":"4_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1471-4159.1986.tb12944.x","volume":"46","author":"TH Andree","year":"1986","unstructured":"Andree TH, Mikuni M, Tong CY, Koenig JI, Meltzer HY (1986) Differential effect of subchronic treatment with various neuroleptic agents on serotonin 2 receptors in rat cerebral cortex. J Neurochem 46(1):191\u2013197","journal-title":"J Neurochem"},{"issue":"2","key":"4_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/0306-4522(91)90128-B","volume":"40","author":"R Araneda","year":"1991","unstructured":"Araneda R, Andrade R (1991) 5-Hydroxytryptamine 2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40(2):399\u2013412","journal-title":"Neuroscience"},{"issue":"2","key":"4_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1592\/phco.24.2.212.33145","volume":"24","author":"TR Argo","year":"2004","unstructured":"Argo TR, Carnahan RM, Perry PJ (2004) Aripiprazole, a novel atypical antipsychotic drug. Pharmacotherapy 24(2):212\u2013228","journal-title":"Pharmacotherapy"},{"issue":"8","key":"4_CR10","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1017\/S1461145710000659","volume":"13","author":"J Arnt","year":"2010","unstructured":"Arnt J, Bang-Andersen B, Grayson B, Bymaster FP, Cohen MP, DeLapp NW, Giethlen B, Kreilgaard M, McKinzie DL, Neill JC, Nelson DL, Nielsen SM, Poulsen MN, Schaus JM, Witten LM (2010) Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol 13(8):1021\u20131033","journal-title":"Int J Neuropsychopharmacol"},{"key":"4_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/B978-0-12-385902-0.00006-1","volume":"96","author":"J Arnt","year":"2011","unstructured":"Arnt J, Olsen CK (2011) 5-HT6 receptor ligands and their antipsychotic potential. Int Rev Neurobiol 96:141\u2013161","journal-title":"Int Rev Neurobiol"},{"key":"4_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","volume":"18","author":"J Arnt","year":"1998","unstructured":"Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63\u2013101","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"4_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1124\/jpet.105.087163","volume":"315","author":"MB Assie\u2019","year":"2005","unstructured":"Assi\u00e9 MB, Ravailhe V, Faucillon V, Newman-Tancredi A (2005) Contrasting contribution of 5-hydroxytryptamine 1a receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 315(1):265\u2013272","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"4_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/026988110101500108","volume":"15","author":"RA Bantick","year":"2001","unstructured":"Bantick RA, Deakin JF, Grasby PM (2001) The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 15(1):37\u201346","journal-title":"J Psychopharmacol"},{"issue":"16","key":"4_CR16","doi-asserted-by":"crossref","first-page":"11687","DOI":"10.1016\/S0021-9258(17)32625-X","volume":"269","author":"EL Barker","year":"1994","unstructured":"Barker EL, Westphal RS, Schmidt D, Sanders-Bush E (1994) Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem 269(16):11687\u201311690","journal-title":"J Biol Chem"},{"issue":"11","key":"4_CR17","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1586\/erc.09.123","volume":"7","author":"HE Bays","year":"2009","unstructured":"Bays HE (2009) Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for \u2018sick fat\u2019 and metabolic disease. Expert Rev Cardiovasc Ther 7(11):1429\u20131445","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"3","key":"4_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1006\/nlme.1998.3886","volume":"71","author":"C Boast","year":"1999","unstructured":"Boast C, Bartolomeo AC, Morris H, Moyer JA (1999) 5HT antagonists attenuate MK801-impaired radial arm maze performance in rats. Neurobiol Learn Mem 71(3):259\u2013271","journal-title":"Neurobiol Learn Mem"},{"issue":"5","key":"4_CR19","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1046\/j.1471-4159.1998.71052169.x","volume":"71","author":"FG Boess","year":"1998","unstructured":"Boess FG, Monsma FJ Jr, Sleight AJ (1998) Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor. J Neurochem 71(5):2169\u20132177","journal-title":"J Neurochem"},{"key":"4_CR20","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S0893-133X(02)00311-1","volume":"27","author":"S Bonaccorso","year":"2002","unstructured":"Bonaccorso S, Meltzer HY, Li Z, Dai J, Alboszta AR, Ichikawa J (2002) SR46349-B, a 5-HT (2A\/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology 27:430\u2013441","journal-title":"Neuropsychopharmacology"},{"key":"4_CR21","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/j.1471-4159.2005.03485.x","volume":"95","author":"A Bortolozzi","year":"2005","unstructured":"Bortolozzi A, Diaz-Mataix L, Scorza MC, Celada P, Artigas F (2005) The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J Neurochem 95:1597\u20131607","journal-title":"J Neurochem"},{"issue":"1\u20133","key":"4_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejphar.2009.08.019","volume":"620","author":"LA Bruins Slot","year":"2009","unstructured":"Bruins Slot LA, Lestienne F, Grevoz-Barret C, Newman-Tancredi A, Cussac D (2009) F15063, a potential antipsychotic with dopamine D(2)\/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum. Eur J Pharmacol 620(1\u20133):27\u201335","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"4_CR23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1176\/ajp.151.3.385","volume":"151","author":"P Buckley","year":"1994","unstructured":"Buckley P, Thompson P, Way L, Meltzer HY (1994) Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry 151(3):385\u2013389","journal-title":"Am J Psychiatry"},{"issue":"5","key":"4_CR24","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0893-133X(96)00053-X","volume":"15","author":"PW Burnet","year":"1996","unstructured":"Burnet PW, Eastwood SL, Harrison PJ (1996) 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 15(5):442\u2013455","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"4_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1021\/jm800689g","volume":"52","author":"S Butini","year":"2009","unstructured":"Butini S, Gemma S, Campiani G et al (2009) Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. J Med Chem 52(1):151\u2013169","journal-title":"J Med Chem"},{"key":"4_CR26","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1471-4159.2008.05789.x","volume":"108","author":"E Calcagno","year":"2009","unstructured":"Calcagno E, Carli M, Baviera M, Invernizzi RW (2009) Endogenous serotonin and serotonin2C receptors are involved in the ability of M100907 to suppress cortical glutamate release induced by NMDA receptor blockade. J Neurochem 108:521\u2013532","journal-title":"J Neurochem"},{"issue":"2","key":"4_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00213-010-1784-0","volume":"209","author":"CE Canal","year":"2010","unstructured":"Canal CE, Olaghere da Silva UB, Gresch PJ, Watt EE, Sanders-Bush E, Airey DC (2010) The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen. Psychopharmacology (Berl) 209(2):163\u2013174","journal-title":"Psychopharmacology (Berl)"},{"issue":"16","key":"4_CR28","doi-asserted-by":"crossref","first-page":"6846","DOI":"10.1523\/JNEUROSCI.22-16-06846.2002","volume":"22","author":"DB Carr","year":"2002","unstructured":"Carr DB, Cooper DC, Ulrich SL, Spruston N, Surmeier DJ (2002) Serotonin receptor activation inhibits sodium current and dendritic excitability in prefrontal cortex via a protein kinase C-dependent mechanism. J Neurosci 22(16):6846\u20136855","journal-title":"J Neurosci"},{"issue":"1","key":"4_CR30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0022-3565(24)35084-0","volume":"291","author":"J Cartmell","year":"1999","unstructured":"Cartmell J, Monn JA, Schoepp DD (1999) The metabotropic glutamate 2\/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291(1):161\u2013170","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"4_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00213-008-1207-7","volume":"200","author":"DE Casey","year":"2008","unstructured":"Casey DE, Sands EE, Heisterberg J, Yang HM (2008) Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology (Berl) 200(3):317\u2013331","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"4_CR32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.intimp.2011.11.011","volume":"12","author":"ML Chen","year":"2012","unstructured":"Chen ML, Tsai TC, Wang LK, Lin YY, Tsai YM, Lee MC, Tsai FM (2012) Risperidone modulates the cytokine and chemokine release of dendritic cells and induces TNF-\u03b1-directed cell apoptosis in neutrophils. Int Immunopharmacol 12(1):197\u2013204","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"4_CR33","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s12031-009-9204-9","volume":"38","author":"YK Choi","year":"2009","unstructured":"Choi YK, Snigdha S, Shahid M, Neill JC, Tarazi FI (2009) Subchronic effects of phencyclidine on dopamine and serotonin receptors: implications for schizophrenia. J Mol Neurosci 38(3):227\u2013235","journal-title":"J Mol Neurosci"},{"key":"4_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.brainres.2004.07.009","volume":"1023","author":"YC Chung","year":"2004","unstructured":"Chung YC, Li Z, Dai J, Meltzer HY, Ichikawa J (2004) Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain Res 1023:54\u201363","journal-title":"Brain Res"},{"key":"4_CR36","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0074-7742(04)59019-0","volume":"59","author":"JT Coyle","year":"2004","unstructured":"Coyle JT, Tsai G (2004) NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. Int Rev Neurobiol 59:491\u2013515","journal-title":"Int Rev Neurobiol"},{"issue":"2","key":"4_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.bbr.2011.01.025","volume":"219","author":"M Creed-Carson","year":"2011","unstructured":"Creed-Carson M, Oraha A, Nobrega JN (2011) Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats. Behav Brain Res 219(2):273\u2013279","journal-title":"Behav Brain Res"},{"issue":"1\u20133","key":"4_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejphar.2008.07.040","volume":"594","author":"D Cussac","year":"2008","unstructured":"Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I (2008) Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq\/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol 594(1\u20133):32\u201338","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"4_CR40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00213-011-2627-3","volume":"222","author":"V Silva Costa-Aze Da","year":"2012","unstructured":"Da Silva Costa-Aze V, Quiedeville A, Boulouard M, Dauphin F (2012) 5-HT6 receptor blockade differentially affects scopolamine-induced deficits of working memory, recognition memory and aversive learning in mice. Psychopharmacology (Berl) 222(1):99\u2013115","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"4_CR41","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.nlm.2011.06.015","volume":"96","author":"NM Bruin de","year":"2011","unstructured":"de Bruin NM, Prickaerts J, van Loevezijn A, Venhorst J, de Groote L, Houba P, Reneerkens O, Akkerman S, Kruse CG (2011) Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats. Neurobiol Learn Mem 96(2):392\u2013402","journal-title":"Neurobiol Learn Mem"},{"issue":"13","key":"4_CR42","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1523\/JNEUROSCI.0112-04.2004","volume":"24","author":"P Deurwaerd\u00e8re De","year":"2004","unstructured":"De Deurwaerd\u00e8re P, Navailles S, Berg KA, Clarke WP, Spampinato U (2004) Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 24(13):3235\u20133241","journal-title":"J Neurosci"},{"issue":"3","key":"4_CR43","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1046\/j.1471-4159.1999.0731033.x","volume":"73","author":"P Deurwaerd\u00e8re De","year":"1999","unstructured":"De Deurwaerd\u00e8re P, Spampinato U (1999) Role of serotonin(2A) and serotonin(2B\/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J Neurochem 73(3):1033\u20131042","journal-title":"J Neurochem"},{"issue":"7","key":"4_CR44","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/j.neuropharm.2012.01.010","volume":"62","author":"HK Delille","year":"2012","unstructured":"Delille HK, Becker JM, Burkhardt S, Bleher B, Terstappen GC, Schmidt M, Meyer AH, Unger L, Marek GJ, Mezler M (2012) Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades. Neuropharmacology 62(7):2184\u20132191","journal-title":"Neuropharmacology"},{"issue":"2","key":"4_CR45","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/sj.bjp.0707160","volume":"151","author":"R Depoort\u00e8re","year":"2007","unstructured":"Depoort\u00e8re R, Auclair AL, Bardin L, Bruins Slot L, Kleven MS, Colpaert F, Vacher B, Newman-Tancredi A (2007) F15063, a compound with D2\/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties III. Activity in models of cognition and negative symptoms. Br J Pharmacol 151(2):266\u2013277","journal-title":"Br J Pharmacol"},{"issue":"11","key":"4_CR46","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1038\/sj.npp.1300261","volume":"28","author":"R Depoortere","year":"2003","unstructured":"Depoortere R, Boulay D, Perrault G, Bergis O, Decobert M, Fran\u00e7on D, Jung M, Simiand J, Soubri\u00e9 P, Scatton B (2003) SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist II: behavioral profile predictive of an atypical antipsychotic activity. Neuropsychopharmacology 28(11):1889\u20131902","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"4_CR47","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0028-3908(99)00047-7","volume":"38","author":"V Matteo Di","year":"1999","unstructured":"Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (1999) SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 38(8):1195\u20131205","journal-title":"Neuropharmacology"},{"issue":"2","key":"4_CR48","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0028-3908(98)00014-8","volume":"37","author":"V Matteo Di","year":"1998","unstructured":"Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (1998) Selective blockade of serotonin2C\/2B receptors enhances dopamine release in the rat nucleus accumbens. Neuropharmacology 37(2):265\u2013272","journal-title":"Neuropharmacology"},{"issue":"47","key":"4_CR49","doi-asserted-by":"publisher","first-page":"10831","DOI":"10.1523\/JNEUROSCI.2999-05.2005","volume":"25","author":"L Diaz-Mataix","year":"2005","unstructured":"Diaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, Artigas F (2005) Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 25(47):10831\u201310843","journal-title":"J Neurosci"},{"issue":"2","key":"4_CR50","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0006-8993(00)02062-X","volume":"864","author":"MD Doherty","year":"2000","unstructured":"Doherty MD, Pickel VM (2000) Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area. Brain Res 864(2):176\u2013185","journal-title":"Brain Res"},{"issue":"3","key":"4_CR51","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00213-011-2207-6","volume":"215","author":"JP Dougherty","year":"2011","unstructured":"Dougherty JP, Aloyo VJ (2011) Pharmacological and behavioral characterization of the 5-HT2A receptor in C57BL\/6N mice. Psychopharmacology (Berl) 215(3):581\u2013593","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"4_CR52","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1124\/jpet.104.075382","volume":"313","author":"J Dunlop","year":"2005","unstructured":"Dunlop J, Sabb AL, Mazandarani H, Zhang J, Kalgaonker S, Shukhina E, Sukoff S, Vogel RL, Stack G, Schechter L, Harrison BL, Rosenzweig-Lipson S (2005) WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J Pharmacol Exp Ther 313(2):862\u2013869","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"4_CR53","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.pnpbp.2007.10.001","volume":"32","author":"N Egashira","year":"2008","unstructured":"Egashira N, Ishigami N, Mishima K, Iwasaki K, Oishi R, Fujiwara M (2008) Delta9-tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats. Prog Neuropsychopharmacol Biol Psychiatry 32(2):499\u2013506","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"12","key":"4_CR237","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/hipo.20596","volume":"19","author":"E Elvander-Tottie","year":"2009","unstructured":"Elvander-Tottie E, Eriksson TM, Sandin J, Ogren SO (2009) 5-HT(1A) and NMDA receptors interact in the rat medial septum and modulate hippocampal-dependent spatial learning. Hippocampus 19(12):1187\u20131198","journal-title":"Hippocampus"},{"issue":"5","key":"4_CR55","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2011.09.055","volume":"147","author":"M Fribourg","year":"2011","unstructured":"Fribourg M, Moreno JL, Holloway T, Provasi D, Baki L, Mahajan R, Park G, Adney SK, Hatcher C, Eltit JM, Ruta JD, Albizu L, Li Z, Umali A, Shim J, Fabiato A, MacKerell AD Jr, Brezina V, Sealfon SC, Filizola M, Gonz\u00e1lez-Maeso J, Logothetis DE (2011) Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 147(5):1011\u20131023","journal-title":"Cell"},{"issue":"2","key":"4_CR56","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/FBP.0b013e3282f62d8c","volume":"19","author":"R Galici","year":"2008","unstructured":"Galici R, Boggs JD, Miller KL, Bonaventure P, Atack JR (2008) Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity. Behav Pharmacol 19(2):153\u2013159","journal-title":"Behav Pharmacol"},{"issue":"2","key":"4_CR57","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1124\/jpet.107.121715","volume":"322","author":"LR Gardell","year":"2007","unstructured":"Gardell LR, Vanover KE, Pounds L, Johnson RW, Barido R, Anderson GT, Veinbergs I, Dyssegaard A, Brunmark P, Tabatabaei A, Davis RE, Brann MR, Hacksell U, Bonhaus DW (2007) ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. J Pharmacol Exp Ther 322(2):862\u2013870","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"4_CR58","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bmcl.2006.10.036","volume":"17","author":"V Garzya","year":"2006","unstructured":"Garzya V, Forbes IT, Gribble AD, Hadley MS, Lightfoot AP, Payne AH, Smith AB, Douglas SE, Cooper DG, Stansfield IG, Meeson M, Dodds EE, Jones DN, Wood M, Reavill C, Scorer CA, Worby A, Riley G, Eddershaw P, Ioannou C, Donati D, Hagan JJ, Ratti EA (2006) Studies towards the identification of a new generation of atypical antipsychotic agents. Bioorg Med Chem Lett 17(2):400\u2013405","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"4_CR59","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0893-133X(00)00136-6","volume":"23","author":"JC Gewirtz","year":"2000","unstructured":"Gewirtz JC, Marek GJ (2000) Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 23(5):569\u2013576","journal-title":"Neuropsychopharmacology"},{"key":"4_CR61","first-page":"212","volume-title":"Current antipsychotics, handbook of experimental pharmacology","author":"N Ginovart","year":"2012","unstructured":"Ginovart N, Kapur S (2012) Role of dopamine D2 receptors for antipsychotic activity. In: Gross G, Geyer MA (eds) Current antipsychotics, vol 212. Handbook of Experimental Pharmacology. Springer, Berlin"},{"key":"4_CR62","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s002130050165","volume":"129","author":"SD Gleason","year":"1997","unstructured":"Gleason SD, Shannon HE (1997) Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology 129:79\u201384","journal-title":"Psychopharmacology"},{"issue":"3","key":"4_CR63","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/schbul\/23.3.437","volume":"23","author":"PS Goldman-Rakic","year":"1997","unstructured":"Goldman-Rakic PS, Selemon LD (1997) Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 23(3):437\u2013458","journal-title":"Schizophr Bull"},{"issue":"7183","key":"4_CR64","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature06612","volume":"452","author":"J Gonz\u00e1lez-Maeso","year":"2008","unstructured":"Gonz\u00e1lez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, L\u00f3pez-Gim\u00e9nez JF, Zhou M, Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, Sealfon SC (2008) Identification of a serotonin\/glutamate receptor complex implicated in psychosis. Nature 452(7183):93\u201397","journal-title":"Nature"},{"issue":"1","key":"4_CR65","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00213-009-1772-4","volume":"209","author":"A Gozzi","year":"2010","unstructured":"Gozzi A, Crestan V, Turrini G, Clemens M, Bifone A (2010) Antagonism at serotonin 5-HT(2A) receptors modulates functional activity of frontohippocampal circuit. Psychopharmacology (Berl) 209(1):37\u201350","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"4_CR66","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/FBP.0b013e328343d804","volume":"22","author":"A Gravius","year":"2011","unstructured":"Gravius A, Laszy J, Pietraszek M, S\u00e1ghy K, Nagel J, Chambon C, Wegener N, Valastro B, Danysz W, Gyerty\u00e1n I (2011) Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity. Behav Pharmacol 22(2):122\u2013135","journal-title":"Behav Pharmacol"},{"issue":"5","key":"4_CR67","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/schbul\/sbm074","volume":"33","author":"JA Gray","year":"2007","unstructured":"Gray JA, Roth BL (2007) Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 33(5):1100\u20131119","journal-title":"Schizophr Bull"},{"issue":"3","key":"4_CR68","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd2806","volume":"8","author":"G Gr\u00fcnder","year":"2009","unstructured":"Gr\u00fcnder G, Hippius H, Carlsson A (2009) The \u2018atypicality\u2019 of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov 8(3):197\u2013202","journal-title":"Nat Rev Drug Discov"},{"issue":"24","key":"4_CR238","doi-asserted-by":"publisher","first-page":"9762","DOI":"10.1073\/pnas.86.24.9762","volume":"86","author":"DK Grandy","year":"1989","unstructured":"Grandy DK, Marchionni MA, Makam H, Stofko RE, Alfano M, Frothingham L, Fischer JB, Burke-Howie KJ, Bunzow JR, Server AC (1989) Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Natl Acad Sci USA 86(24):9762\u20139976","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"4_CR70","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00213-008-1433-z","volume":"204","author":"SM Grauer","year":"2009","unstructured":"Grauer SM, Graf R, Navarra R, Sung A, Logue SF, Stack G, Huselton C, Liu Z, Comery TA, Marquis KL, Rosenzweig-Lipson S (2009) WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics. Psychopharmacology (Berl) 204(1):37\u201348","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"4_CR71","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.bbr.2007.06.012","volume":"184","author":"BI Grayson","year":"2007","unstructured":"Grayson BI, Idris NF, Neill JC (2007) Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 184(1):31\u201338","journal-title":"Behav Brain Res"},{"issue":"4","key":"4_CR72","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.neuroscience.2008.08.033","volume":"156","author":"B Gronier","year":"2008","unstructured":"Gronier B (2008) Involvement of glutamate neurotransmission and N-methyl-d-aspartate receptor in the activation of midbrain dopamine neurons by 5-HT1A receptor agonists: an electrophysiological study in the rat. Neuroscience 156(4):995\u20131004","journal-title":"Neuroscience"},{"key":"4_CR73","volume-title":"Novel antischizophrenia treatments; handbook of experimental pharmacology","author":"G Gross","year":"2012","unstructured":"Gross G, Drescher K (2012) The role of dopamine D3 receptors in antipsychotic activity and cognitive functions. In: Geyer M, Gross G (eds) Novel antischizophrenia treatments; Handbook of Experimental Pharmacology, vol 213. Springer, Heidelberg"},{"issue":"4","key":"4_CR69","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1124\/mol.106.032490","volume":"71","author":"Z Gu","year":"2007","unstructured":"Gu Z, Jiang Q, Yan Z (2007) RGS4 modulates serotonin signaling in prefrontal cortex and links to serotonin dysfunction in a rat model of schizophrenia. Mol Pharmacol 71(4):1030\u20131039","journal-title":"Mol Pharmacol"},{"issue":"6","key":"4_CR60","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.neuint.2011.07.002","volume":"59","author":"I Gyerty\u00e1n","year":"2011","unstructured":"Gyerty\u00e1n I, Kiss B, S\u00e1ghy K, Laszy J, Szab\u00f3 G, Szabados T, G\u00e9mesi LI, P\u00e1sztor G, Z\u00e1jer-Bal\u00e1zs M, Kap\u00e1s M, Csongor E\u00c1, Dom\u00e1ny G, Tihanyi K, Szombathelyi Z (2011) Cariprazine (RGH-188), a potent D3\/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int 59(6):925\u2013935","journal-title":"Neurochem Int"},{"issue":"6","key":"4_CR74","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.euroneuro.2007.11.005","volume":"18","author":"H Hagiwara","year":"2008","unstructured":"Hagiwara H, Fujita Y, Ishima T, Kunitachi S, Shirayama Y, Iyo M, Hashimoto K (2008) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors. Eur Neuropsychopharmacol 18(6):448\u2013454","journal-title":"Eur Neuropsychopharmacol"},{"key":"4_CR75","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/0006-3223(93)90043-D","volume":"34","author":"C Hagger","year":"1993","unstructured":"Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY (1993) Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34:702\u2013712","journal-title":"Biol Psychiatry"},{"issue":"7","key":"4_CR76","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1073\/pnas.1117104109","volume":"109","author":"A Hahn","year":"2012","unstructured":"Hahn A, Wadsak W, Windischberger C, Baldinger P, H\u00f6flich AS, Losak J, Nics L, Philippe C, Kranz GS, Kraus C, Mitterhauser M, Karanikas G, Kasper S, Lanzenberger R (2012) Differential modulation of the default mode network via serotonin-1A receptors. Proc Natl Acad Sci USA 109(7):2619\u20132624","journal-title":"Proc Natl Acad Sci USA"},{"key":"4_CR77","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejphar.2005.07.002","volume":"519","author":"K Hashimoto","year":"2005","unstructured":"Hashimoto K, Fujita Y, Shimizu E, Iyo M (2005) Phencyclidine-induced cognitive deficits in mice are improved by subsequent sub-chronic administration of clozapine, but not haloperidol. Eur J Pharmacol 519:114\u2013117","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"4_CR78","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00213-009-1626-0","volume":"206","author":"PB Hedlund","year":"2009","unstructured":"Hedlund PB (2009) The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl) 206(3):345\u2013354","journal-title":"Psychopharmacology (Berl)"},{"issue":"9","key":"4_CR79","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.tips.2004.07.002","volume":"25","author":"PB Hedlund","year":"2004","unstructured":"Hedlund PB, Sutcliffe JG (2004) Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol Sci 25(9):481\u2013486","journal-title":"Trends Pharmacol Sci"},{"key":"4_CR80","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0028-3908(02)00332-5","volume":"43","author":"SA Henry","year":"2002","unstructured":"Henry SA, Lehmann-Masten V, Gasparini F, Geyer MA, Markou A (2002) The mGLUR5 antagonist MPEP, but not the mGLUR2\/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 43:1199\u20131209","journal-title":"Neuropharmacology"},{"issue":"1","key":"4_CR81","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0022-3565(24)38891-3","volume":"295","author":"K Herrick-Davis","year":"2000","unstructured":"Herrick-Davis K, Grinde E, Teitler M (2000) Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 295(1):226\u2013232","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"4_CR82","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/S0968-0896(98)00167-9","volume":"6","author":"EJ Homan","year":"1998","unstructured":"Homan EJ, Copinga S, Elfstr\u00f6m L (1998) 2-aminotetralin-derived substituted benzamides with mixed dopamine D2, D3, and serotonin 5-HT1A receptor binding properties: a novel class of potential atypical antipsychotic agents. Bioorg Med Chem 6(11):2111\u20132126","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"4_CR83","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1124\/jpet.111.180638","volume":"338","author":"M Horiguchi","year":"2011","unstructured":"Horiguchi M, Huang M, Meltzer HY (2011a) The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther 338(2):605\u2013614","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"4_CR84","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00213-011-2251-2","volume":"217","author":"M Horiguchi","year":"2011","unstructured":"Horiguchi M, Huang M, Meltzer HY (2011b) Interaction of mGlu2\/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. Psychopharmacology (Berl) 217(1):13\u201324","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"4_CR85","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00213-011-2561-4","volume":"221","author":"M Horiguchi","year":"2012","unstructured":"Horiguchi M, Meltzer HY (2012) The role of 5-HT(1A) receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. Psychopharmacology (Berl) 221(2):205\u2013215","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"4_CR86","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.bbr.2011.01.034","volume":"220","author":"T Horisawa","year":"2011","unstructured":"Horisawa T, Ishibashi T, Nishikawa H, Enomoto T, Toma S, Ishiyama T, Taiji M (2011) The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behav Brain Res 220(1):83\u201390","journal-title":"Behav Brain Res"},{"issue":"3","key":"4_CR87","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/schbul\/sbp006","volume":"35","author":"OD Howes","year":"2009","unstructured":"Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III\u2013the final common pathway. Schizophr Bull 35(3):549\u2013562","journal-title":"Schizophr Bull"},{"issue":"1","key":"4_CR88","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0006-8993(86)90903-0","volume":"376","author":"D Hoyer","year":"1986","unstructured":"Hoyer D, Pazos A, Probst A, Palacios JM (1986) Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites. Brain Res 376(1):97\u2013107","journal-title":"Brain Res"},{"issue":"1\u20133","key":"4_CR239","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejphar.2010.10.094","volume":"652","author":"M Huang","year":"2011","unstructured":"Huang M, Dai J, Meltzer HY (2011) 5-HT(2A) and 5-HT(2C) receptor stimulation are differentially involved in the cortical dopamine efflux-studied in 5-HT(2A) and 5-HT(2C) genetic mutant mice. Eur J Pharmacol 652(1\u20133):40\u201345","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"4_CR89","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/WNR.0b013e328352de40","volume":"23","author":"M Huang","year":"2012","unstructured":"Huang M, Horiguchi M, Felix AR, Meltzer HY (2012) 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport 23(7):436\u2013440","journal-title":"Neuroreport"},{"issue":"4","key":"4_CR91","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00213-007-0921-x","volume":"195","author":"R Hurlemann","year":"2008","unstructured":"Hurlemann R, Matusch A, Kuhn KU, Berning J, Elmenhorst D, Winz O, Kolsch H, Zilles K, Wagner M, Maier W, Bauer A (2008) A 5-HT2A receptor density is decreased in the at-risk mental state. Psychopharmacology (Berl) 195(4):579\u2013590","journal-title":"Psychopharmacology (Berl)"},{"issue":"1\u20132","key":"4_CR240","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/0006-8993(92)90805-J","volume":"574","author":"J Ichikawa","year":"1992","unstructured":"Ichikawa J, Meltzer HY (1992) The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo. Brain Res 574(1\u20132):98\u2013104","journal-title":"Brain Res"},{"issue":"5","key":"4_CR92","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1046\/j.1471-4159.2001.00154.x","volume":"76","author":"J Ichikawa","year":"2001","unstructured":"Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O\u2019Laughlin IA, Meltzer HY (2001) 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76(5):1521\u20131531","journal-title":"J Neurochem"},{"issue":"2","key":"4_CR93","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0006-8993(02)03570-9","volume":"956","author":"J Ichikawa","year":"2002","unstructured":"Ichikawa J, Li Z, Dai J, Meltzer HY (2002a) Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 956(2):349\u2013357","journal-title":"Brain Res"},{"issue":"3","key":"4_CR94","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0893-133X(01)00312-8","volume":"26","author":"J Ichikawa","year":"2002","unstructured":"Ichikawa J, Dai J, O\u2019Laughlin IA, Dai J, Fowler W, Meltzer HY (2002b) Atypical, but not typical, antipsychotic drugs selectively increase acetylcholine release in rat medial prefrontal cortex, nucleus accumbens and striatum. Neuropsychopharmacology 26(3):325\u2013339","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"4_CR95","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0006-8993(99)02237-4","volume":"853","author":"K Ikemoto","year":"2000","unstructured":"Ikemoto K, Nishimura A, Okado N, Mikuni M, Nishi K, Nagatsu I (2000) Human midbrain dopamine neurons express serotonin 2A receptor: an immunohistochemical demonstration. Brain Res 853(2):377\u2013380","journal-title":"Brain Res"},{"issue":"1","key":"4_CR96","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1124\/jpet.110.167346","volume":"334","author":"T Ishibashi","year":"2010","unstructured":"Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M (2010) Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 334(1):171\u2013181","journal-title":"J Pharmacol Exp Ther"},{"key":"4_CR97","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0014-2999(96)00948-X","volume":"321","author":"T Ishikane","year":"1997","unstructured":"Ishikane T, Kusumi I, Matsubara R, Matsubara S, Koyama T (1997) Effects of serotonergic agents on the up-regulation of dopamine D2 receptors induced by haloperidol in rat striatum. Eur J Pharmacol 321:163\u2013169","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"4_CR98","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.nbd.2010.04.017","volume":"39","author":"G Issa","year":"2010","unstructured":"Issa G, Wilson C, Terry AV Jr, Pillai A (2010) An inverse relationship between cortisol and BDNF levels in schizophrenia: data from human postmortem and animal studies. Neurobiol Dis 39(3):327\u2013333","journal-title":"Neurobiol Dis"},{"key":"4_CR99","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1073\/pnas.95.2.735","volume":"95","author":"RL Jakab","year":"1998","unstructured":"Jakab RL, Goldman-Rakic PS (1998) 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci USA 95:735\u2013740","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"4_CR100","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S0893-133X(01)00285-8","volume":"25","author":"HO Kalkman","year":"2001","unstructured":"Kalkman HO, Subramanian N, Hoyer D (2001) Extended radioligand binding profile of iloperidone: a broad spectrum dopamine\/serotonin\/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 25(6):904\u2013914","journal-title":"Neuropsychopharmacology"},{"key":"4_CR101","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789\u2013796","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"4_CR103","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bbr.2007.07.033","volume":"186","author":"J Karasawa","year":"2008","unstructured":"Karasawa J, Hashimoto K, Chaki S (2008) D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res 186(1):78\u201383","journal-title":"Behav Brain Res"},{"issue":"3","key":"4_CR102","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/npp.2011.249","volume":"37","author":"L Kargieman","year":"2012","unstructured":"Kargieman L, Riga MS, Artigas F, Celada P (2012) Clozapine reverses phencyclidine-induced desynchronization of prefrontal cortex through a 5-HT(1A) receptor-dependent mechanism. Neuropsychopharmacology 37(3):723\u2013733","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"4_CR104","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0022-3565(25)12956-X","volume":"277","author":"JH Kehne","year":"1996","unstructured":"Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, Frank RA, van Giersbergen PL, McCloskey TC, Johnson MP, McCarty DR, Poirot M, Senyah Y, Siegel BW, Widmaier C (1996) Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277(2):968\u2013981","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"4_CR105","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0091-3057(93)90277-Z","volume":"44","author":"K Kimura","year":"1993","unstructured":"Kimura K, Nomikos GG, Svensson TH (1993) Effects of amperozide on psychostimulant-induced hyperlocomotion and dopamine release in the nucleus accumbens. Pharmacol Biochem Behav 44(1):27\u201336","journal-title":"Pharmacol Biochem Behav"},{"key":"4_CR106","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/jpet.109.160432","volume":"333","author":"B Kiss","year":"2010","unstructured":"Kiss B, Horv\u00e1th A, N\u00e9methy Z, Schmidt E, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyerty\u00e1n I, Agai-Csongor E, Dom\u00e1ny G, Tihanyi K, Adham N, Szombathelyi Z (2010) Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3\/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 333:328\u2013340","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"4_CR107","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.neuropharm.2005.02.005","volume":"49","author":"MS Kleven","year":"2005","unstructured":"Kleven MS, Barret-Gr\u00e9voz C, Bruins Slot L, Newman-Tancredi A (2005) Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology 49(2):135\u2013143","journal-title":"Neuropharmacology"},{"issue":"1","key":"4_CR108","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1046\/j.1471-4159.1996.66010047.x","volume":"66","author":"R Kohen","year":"1996","unstructured":"Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE, Meltzer HY, Sibley DR, Roth BL, Hamblin MW (1996) Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem 66(1):47\u201356","journal-title":"J Neurochem"},{"key":"4_CR241","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0014-2999(96)00840-0","volume":"317","author":"S Kongsamut","year":"1996","unstructured":"Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A (1996) Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol 317:417\u2013423","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"4_CR110","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/cmdc.201000186","volume":"5","author":"AP Kozikowski","year":"2010","unstructured":"Kozikowski AP, Cho SJ, Jensen NH, Allen JA, Svennebring AM, Roth BL (2010) HTS and rational drug design to generate a class of 5-HT(2C)-selective ligands for possible use in schizophrenia. ChemMedChem 5(8):1221\u20131225","journal-title":"ChemMedChem"},{"issue":"1\u20132","key":"4_CR111","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0006-8993(00)02574-9","volume":"875","author":"PJ Kruzich","year":"2000","unstructured":"Kruzich PJ, See RE (2000) An evaluation of the role of 5-HT(2) receptor antagonism during subchronic antipsychotic drug administration in rats. Brain Res 875(1\u20132):35\u201343","journal-title":"Brain Res"},{"issue":"2","key":"4_CR112","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0022-3565(24)38019-X","volume":"288","author":"T Kuroki","year":"1999","unstructured":"Kuroki T, Meltzer HY, Ichikawa J (1999) Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288(2):774\u2013781","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"4_CR113","first-page":"211","volume":"42","author":"M Laruelle","year":"1998","unstructured":"Laruelle M (1998) Imaging dopamine transmission in schizophrenia. A review and meta-analysis. A review and meta-analysis. Q J Nucl Med 42(3):211\u2013221","journal-title":"Q J Nucl Med"},{"issue":"2","key":"4_CR115","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1471-4159.2009.06356.x","volume":"111","author":"GM Leggio","year":"2009","unstructured":"Leggio GM, Cathala A, Neny M, Rouge-Pont F, Drago F, Piazza PV, Spampinato U (2009) In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist. J Neurochem 111(2):614\u2013623","journal-title":"J Neurochem"},{"issue":"2","key":"4_CR116","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0091-3057(03)00082-0","volume":"75","author":"A Leng","year":"2003","unstructured":"Leng A, Ouagazzal A, Feldon J, Higgins GA (2003) Effect of the 5-HT6 receptor antagonists Ro04-6790 and Ro65-7199 on latent inhibition and prepulse inhibition in the rat: comparison to clozapine. Pharmacol Biochem Behav 75(2):281\u2013288","journal-title":"Pharmacol Biochem Behav"},{"issue":"4","key":"4_CR117","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nrn1648","volume":"6","author":"DA Lewis","year":"2005","unstructured":"Lewis DA, Hashimoto T, Volk DW (2005) Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6(4):312\u2013324","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"4_CR118","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/BF00178504","volume":"188","author":"JE Leysen","year":"1986","unstructured":"Leysen JE, Van Gompel P, Gommeren W, Woestenborghs R, Janssen PA (1986) Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone. Psychopharmacology (Berl) 188(4):434\u2013444","journal-title":"Psychopharmacology (Berl)"},{"key":"4_CR90","unstructured":"Li Z, AJ, Ichikawa J, Dai J, and Meltzer HY (2005) 5-HT2a and 5-HT2c receptor antagonism enhances risperidone-induced dopamine (DA) efflux in rat medial prefrontal cortex (mPFC) and diminishes it in the nucleus accumbens (NAC). Neurosci Abs 914.10"},{"issue":"2","key":"4_CR119","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00213-005-0170-9","volume":"183","author":"Z Li","year":"2005","unstructured":"Li Z, Ichikawa J, Huang M, Prus AJ, Dai J, Meltzer HY (2005) ACP-103, a 5-HT2A\/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl) 183(2):144\u2013153","journal-title":"Psychopharmacology (Berl)"},{"key":"4_CR120","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0006-8993(02)02620-3","volume":"947","author":"J-F Liegeois","year":"2002","unstructured":"Liegeois J-F, Ichikawa J, Meltzer HY (2002) 5HT2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 947:157\u2013165","journal-title":"Brain Res"},{"issue":"6","key":"4_CR121","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/j.1365-2125.2011.03902.x","volume":"71","author":"M Liem-Moolenaar","year":"2011","unstructured":"Liem-Moolenaar M, Rad M, Zamuner S, Cohen AF, Lemme F, Franson KL, van Gerven JM, Pich EM (2011) Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men. Br J Clin Pharmacol 71(6):907\u2013916","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"4_CR242","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pnpbp.2011.08.022","volume":"36","author":"VM Linck","year":"2012","unstructured":"Linck VM, Bessa MM, Herrmann AP, Iwu MM, Okunji CO, Elisabetsky E (2012) 5-HT2A\/C receptors mediate the antipsychotic-like effects of alstonine. Prog Neuropsychopharmacol Biol Psychiatry 36(1):29\u201333","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"7","key":"4_CR122","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/cercor\/bhr220","volume":"22","author":"L Llado \u0301-Pelfort","year":"2012","unstructured":"Llad\u00f3-Pelfort L, Santana N, Ghisi V, Artigas F, Celada P (2012) 5-HT1A Receptor agonists 1304 enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA 1305 interneurons. Cereb Cortex 22(7):1487\u20131497","journal-title":"Cereb Cortex"},{"issue":"1","key":"4_CR123","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0022-3565(24)35262-0","volume":"292","author":"GJ Marek","year":"2000","unstructured":"Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK (2000) Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 292(1):76\u201387","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"4_CR124","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1210\/jc.2010-1848","volume":"96","author":"CK Martin","year":"2011","unstructured":"Martin CK, Redman LM, Zhang J, Sanchez M, Anderson CM, Smith SR, Ravussin E (2011) Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab 96(3):837\u2013845","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"4_CR125","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/sj.bjp.0705576","volume":"141","author":"FJ Mart\u00edn-Cora","year":"2004","unstructured":"Mart\u00edn-Cora FJ, Pazos A (2004) Autoradiographic distribution of 5-HT7 receptors in the human brain using [3H]mesulergine: comparison to other mammalian species. Br J Pharmacol 141(1):92\u2013104","journal-title":"Br J Pharmacol"},{"issue":"4\u20135","key":"4_CR127","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/BF01277672","volume":"104","author":"P Martin","year":"1997","unstructured":"Martin P, Waters N, Carlsson A, Carlsson ML (1997) The apparent antipsychotic action of the 5-HT2A receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. J Neural Transm 104(4\u20135):561\u2013564","journal-title":"J Neural Transm"},{"issue":"18","key":"4_CR130","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.2174\/092986711796011283","volume":"18","author":"D Marazziti","year":"2011","unstructured":"Marazziti D, Baroni S, Catena Dell\u2019Osso M, Bordi F, Borsini F (2011) Serotonin receptors of type 6 (5-HT6): what can we expect from them? Curr Med Chem 18(18):2783\u20132790","journal-title":"Curr Med Chem"},{"issue":"9","key":"4_CR131","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/070674370505000907","volume":"50","author":"HC Margolese","year":"2005","unstructured":"Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R (2005a) Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry 50(9):541\u2013547","journal-title":"Can J Psychiatry"},{"issue":"11","key":"4_CR132","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/070674370505001110","volume":"50","author":"HC Margolese","year":"2005","unstructured":"Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable (2005b) Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry 50(11):703\u2013714","journal-title":"Can J Psychiatry"},{"issue":"4\u20135","key":"4_CR133","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s007020050064","volume":"105","author":"P Martin","year":"1998","unstructured":"Martin P, Waters N, Schmidt CJ, Carlsson A, Carlsson ML (1998) Rodent data and general hypothesis: antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone. J Neural Transm 105(4\u20135):365\u2013396","journal-title":"J Neural Transm"},{"issue":"1","key":"4_CR244","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1124\/jpet.106.106989","volume":"320","author":"KL Marquis","year":"2007","unstructured":"Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR Jr, Nguyen HQ, Dawson LA, Barrett JE, Stack G, Meltzer HY, Harrison BL, Rosenzweig-Lipson S (2007) WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther 320(1):486\u2013496","journal-title":"J Pharmacol Exp Ther"},{"issue":"15","key":"4_CR134","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/0024-3205(89)90027-1","volume":"45","author":"S Matsubara","year":"1989","unstructured":"Matsubara S, Meltzer HY (1989) Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex. Life Sci 45(15):1397\u20131406","journal-title":"Life Sci"},{"issue":"3","key":"4_CR128","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.neulet.2004.12.059","volume":"379","author":"I Matsumoto","year":"2005","unstructured":"Matsumoto I, Inoue Y, Iwazaki T, Pavey G, Dean B (2005) 5-HT2A and muscarinic receptors in schizophrenia: a postmortem study. Neurosci Lett 379(3):164\u2013168","journal-title":"Neurosci Lett"},{"key":"4_CR135","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.brainres.2007.12.010","volume":"1195","author":"M Matsumoto","year":"2008","unstructured":"Matsumoto M, Shikanai H, Togashi H, Izumi T, Kitta T, Hirata R, Yamaguchi T, Yoshioka M (2008) Characterization of clozapine-induced changes in synaptic plasticity in the hippocampal-mPFC pathway of anesthetized rats. Brain Res 1195:50\u201355","journal-title":"Brain Res"},{"issue":"6","key":"4_CR129","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.euroneuro.2009.01.009","volume":"19","author":"SL McLean","year":"2009","unstructured":"McLean SL, Idris NF, Woolley ML, Neill JC (2009) D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: implications for mechanisms of improved cognitive function in schizophrenia. Eur Neuropsychopharmacol 19(6):440\u2013450","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"4_CR243","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.bbr.2010.05.043","volume":"214","author":"SL McLean","year":"2010","unstructured":"McLean SL, Neill JC, Idris NF, Marston HM, Wong EH, Shahid M (2010) Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat. Behav Brain Res 214(2):240\u2013247","journal-title":"Behav Brain Res"},{"issue":"19","key":"4_CR136","doi-asserted-by":"crossref","first-page":"7781","DOI":"10.1523\/JNEUROSCI.21-19-07781.2001","volume":"21","author":"LR McMahon","year":"2001","unstructured":"McMahon LR, Filip M, Cunningham KA (2001) Differential regulation of the mesoaccumbens circuit by serotonin 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Neurosci 21(19):7781\u20137787","journal-title":"J Neurosci"},{"issue":"1","key":"4_CR137","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0091-3057(93)90327-P","volume":"46","author":"BA McMillen","year":"1993","unstructured":"McMillen BA, Jones EA, Hill LJ, Williams HL, Bj\u00f6rk A, Myers RD (1993) Amperozide, a 5-HT2 antagonist, attenuates craving for cocaine by rats. Pharmacol Biochem Behav 46(1):125\u2013129","journal-title":"Pharmacol Biochem Behav"},{"issue":"7","key":"4_CR138","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/archpsyc.1989.01810070098017","volume":"46","author":"HY Meltzer","year":"1989","unstructured":"Meltzer HY (1989) Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Arch Gen Psychiatry 46(7):672","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"4_CR245","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0193-953X(18)30179-5","volume":"16","author":"HY Meltzer","year":"1993","unstructured":"Meltzer HY (1993) New drugs for the treatment of schizophrenia. Psychiatr Clin North Am 16(2):365\u2013385","journal-title":"Psychiatr Clin North Am"},{"issue":"6","key":"4_CR139","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","volume":"161","author":"HY Meltzer","year":"2004","unstructured":"Meltzer HY, Arvanitis L, Bauer D, Rein W, Meta-Trial Study Group (2004) Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161(6):975\u2013984","journal-title":"Am J Psychiatry"},{"key":"4_CR140","doi-asserted-by":"crossref","unstructured":"Meltzer HY, Elkis H, Vanover IK, Weiner DM, van Kammen DP, Peters P, Hacksell U (2012) Pimavanserin,a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone 2\u00a0mg\/day but does not enhance eficacy of haloperidol 2\u00a0mg\/day: comparison with reference dose risperidone, 6\u00a0mg\/day. Schizr Res (in press)","DOI":"10.1016\/j.schres.2012.07.029"},{"issue":"2\u20133","key":"4_CR141","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00213-010-2137-8","volume":"213","author":"HY Meltzer","year":"2011","unstructured":"Meltzer HY, Horiguchi M, Massey BW (2011) The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl) 213(2\u20133):289\u2013305","journal-title":"Psychopharmacology (Berl)"},{"key":"4_CR142","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0079-6123(08)00909-6","volume":"172","author":"HY Meltzer","year":"2008","unstructured":"Meltzer HY, Huang M (2008) In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 172:177\u2013197","journal-title":"Prog Brain Res"},{"issue":"7","key":"4_CR143","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","volume":"27","author":"HY Meltzer","year":"2003","unstructured":"Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27(7):1159\u20131172","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"8","key":"4_CR144","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.2174\/138920112800784880","volume":"13","author":"HY Meltzer","year":"2012","unstructured":"Meltzer HY, Massey BW, Horiguchi M (2012) Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr Pharm Biotechnol 13(8):1572\u201386","journal-title":"Curr Pharm Biotechnol"},{"key":"4_CR145","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","volume":"251","author":"HY Meltzer","year":"1989","unstructured":"Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2, and serotonin2 pKi values. J Pharmacol Exp Ther 251:238\u2013246","journal-title":"J Pharmacol Exp Ther"},{"key":"4_CR146","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","volume":"25","author":"HY Meltzer","year":"1999","unstructured":"Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233\u2013255","journal-title":"Schizophr Bull"},{"issue":"4","key":"4_CR147","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/npp.2009.176","volume":"35","author":"HY Meltzer","year":"2010","unstructured":"Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH (2010) Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson\u2019s disease psychosis. Neuropsychopharmacology 35(4):881\u2013892","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"4_CR148","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/schbul\/2.1.19","volume":"2","author":"HY Meltzer","year":"1976","unstructured":"Meltzer HY, Stahl SM (1976) The dopamine hypothesis of schizophrenia: a review. Schizophr Bull 2(1):19\u201376","journal-title":"Schizophr Bull"},{"issue":"2","key":"4_CR149","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.bbr.2004.04.026","volume":"155","author":"A Meneses","year":"2004","unstructured":"Meneses A (2004) Effects of the 5-HT7 receptor antagonists SB-269970 and DR 4004 in autoshaping Pavlovian\/instrumental learning task. Behav Brain Res 155(2):275\u2013282","journal-title":"Behav Brain Res"},{"issue":"5","key":"4_CR150","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.neubiorev.2007.02.001","volume":"31","author":"A Meneses","year":"2007","unstructured":"Meneses A, Perez-Garcia G (2007) 5-HT(1A) receptors and memory. Neurosci Biobehav Rev 31(5):705\u2013727","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"4_CR151","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00213-009-1754-6","volume":"208","author":"U Meyer","year":"2010","unstructured":"Meyer U, Knuesel I, Nyffeler M, Feldon J (2010) Chronic clozapine treatment improves prenatal infection-induced working memory deficits without influencing adult hippocampal neurogenesis. Psychopharmacology (Berl) 208(4):531\u2013534","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"4_CR152","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrd3628","volume":"11","author":"MJ Millan","year":"2012","unstructured":"Millan MJ, Agid Y, Br\u00fcne M, Bullmore ET, Carter CS, Clayton NS, Connor R, Davis S, Deakin B, DeRubeis RJ, Dubois B, Geyer MA, Goodwin GM, Gorwood P, Jay TM, Jo\u00ebls M, Mansuy IM, Meyer-Lindenberg A, Murphy D, Rolls E, Saletu B, Spedding M, Sweeney J, Whittington M, Young LJ (2012) Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov 11(2):141\u2013168","journal-title":"Nat Rev Drug Discov"},{"key":"4_CR153","doi-asserted-by":"publisher","first-page":"4419","DOI":"10.1046\/j.1460-9568.1999.00858.x","volume":"11","author":"MJ Millan","year":"1999","unstructured":"Millan MJ, Brocco M, Gobert A, Joly F, Bervoets K, Rivet JM, Newman-Tancredi A, Audinot V, Maurel S (1999) Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A site for PCP-induced locomotion in the rat. Eur J Neurosci 11:4419\u20134432","journal-title":"Eur J Neurosci"},{"issue":"1","key":"4_CR154","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.mp.4001556","volume":"10","author":"S Miyamoto","year":"2005","unstructured":"Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10(1):79\u2013104","journal-title":"Mol Psychiatry"},{"issue":"3","key":"4_CR155","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0026-895X(25)13616-X","volume":"43","author":"FJ Monsma Jr","year":"1993","unstructured":"Monsma FJ Jr, Shen Y, Ward RP, Hamblin MW, Sibley DR (1993) Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 43(3):320\u2013332","journal-title":"Mol Pharmacol"},{"issue":"5","key":"4_CR156","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1523\/JNEUROSCI.4230-10.2011","volume":"31","author":"JL Moreno","year":"2011","unstructured":"Moreno JL, Kurita M, Holloway T, L\u00f3pez J, Cadagan R, Mart\u00ednez-Sobrido L, Garc\u00eda-Sastre A, Gonz\u00e1lez-Maeso J (2011) Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT2A and mGlu2 receptors in the adult offspring. J Neurosci 31(5):1863\u20131872","journal-title":"J Neurosci"},{"issue":"4","key":"4_CR246","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1006\/brbi.1998.0532","volume":"12","author":"R M\u00f6ssner","year":"1998","unstructured":"M\u00f6ssner R, Lesch KP (1998) Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun 12(4):249\u2013271","journal-title":"Brain Behav Immun"},{"issue":"1\u20133","key":"4_CR157","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00213-008-1240-6","volume":"202","author":"T Nagai","year":"2009","unstructured":"Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H, Nabeshima T (2009) Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl) 202(1\u20133):315\u2013328","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"4_CR158","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.neures.2006.06.002","volume":"56","author":"H Nawa","year":"2006","unstructured":"Nawa H, Takei N (2006) Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neurosci Res 56(1):2\u201313","journal-title":"Neurosci Res"},{"issue":"3","key":"4_CR159","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","volume":"128","author":"JC Neill","year":"2010","unstructured":"Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, Harte MK (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 128(3):419\u2013432","journal-title":"Pharmacol Ther"},{"issue":"7","key":"4_CR160","first-page":"802","volume":"11","author":"A Newman-Tancredi","year":"2010","unstructured":"Newman-Tancredi A (2010) The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs 11(7):802\u2013812","journal-title":"Curr Opin Investig Drugs"},{"issue":"2\u20133","key":"4_CR161","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0014-2999(98)00483-X","volume":"355","author":"A Newman-Tancredi","year":"1998","unstructured":"Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verri\u00e8le L, Audinot V, Millan MJ (1998) Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol 355(2\u20133):245\u2013256","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"4_CR162","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nn.2469","volume":"13","author":"QT Nguyen","year":"2010","unstructured":"Nguyen QT, Schroeder LF, Mank M, Muller A, Taylor P, Griesbeck O, Kleinfeld D (2010) An in vivo biosensor for neurotransmitter release and in situ receptor activity. Nat Neurosci 13(1):127\u2013132","journal-title":"Nat Neurosci"},{"key":"4_CR163","doi-asserted-by":"crossref","first-page":"475108","DOI":"10.1155\/2009\/475108","volume":"2009","author":"CD Nichols","year":"2009","unstructured":"Nichols CD (2009) Serotonin 5-HT(2A) receptor function as a contributing factor to both neuropsychiatric and cardiovascular diseases. Cardiovasc Psychiatry Neurol 2009:475108","journal-title":"Cardiovasc Psychiatry Neurol"},{"issue":"2\u20133","key":"4_CR165","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.neuropharm.2010.08.019","volume":"60","author":"Y Ohno","year":"2011","unstructured":"Ohno Y, Imaki J, Mae Y, Takahashi T, Tatara A (2011) Serotonergic modulation of extrapyramidal motor disorders in mice and rats: role of striatal 5-HT3 and 5-HT6 receptors. Neuropharmacology 60(2\u20133):201\u2013208","journal-title":"Neuropharmacology"},{"issue":"1","key":"4_CR166","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0022-3565(25)10246-2","volume":"264","author":"M Oka","year":"1993","unstructured":"Oka M, Noda Y, Ochi Y, Furukawa K, Une T, Kurumiya S, Hino K, Karasawa T (1993) Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther 264(1):158\u2013165","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"4_CR167","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.nbd.2011.08.026","volume":"45","author":"RT O\u2019Neil","year":"2012","unstructured":"O\u2019Neil RT, Emeson RB (2012) Quantitative analysis of 5HT(2C) receptor RNA editing patterns in psychiatric disorders. Neurobiol Dis 45(1):8\u201313","journal-title":"Neurobiol Dis"},{"key":"4_CR168","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0022-3565(24)36626-1","volume":"281","author":"MA Parada","year":"1997","unstructured":"Parada MA, Hernandez L, Puig de Parada M, Rada P, Murzi E (1997) Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum. J Pharmacol Exp Ther 281:582\u2013588","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"4_CR169","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/nm1632","volume":"13","author":"ST Patil","year":"2007","unstructured":"Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD (2007) Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13(9):1102\u20131107","journal-title":"Nat Med"},{"issue":"2","key":"4_CR170","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.bbr.2007.11.010","volume":"188","author":"N Pitsikas","year":"2008","unstructured":"Pitsikas N, Zisopoulou S, Pappas I, Sakellaridis N (2008) The selective 5-HT(6) receptor antagonist Ro 04-6790 attenuates psychotomimetic effects of the NMDA receptor antagonist MK-801. Behav Brain Res 188(2):304\u2013309","journal-title":"Behav Brain Res"},{"issue":"2","key":"4_CR171","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0026-895X(25)13130-1","volume":"44","author":"JL Plassat","year":"1993","unstructured":"Plassat JL, Amlaiky N, Hen R (1993) Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol Pharmacol 44(2):229\u2013236","journal-title":"Mol Pharmacol"},{"issue":"4","key":"4_CR172","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0091-3057(01)00744-4","volume":"71","author":"B Pouzet","year":"2002","unstructured":"Pouzet B, Didriksen M, Arnt J (2002) Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia. Pharmacol Biochem Behav 71(4):655\u2013665","journal-title":"Pharmacol Biochem Behav"},{"issue":"2\u20133","key":"4_CR173","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0014-2999(02)02430-5","volume":"453","author":"EP Prinssen","year":"2002","unstructured":"Prinssen EP, Colpaert FC, Koek W (2002) 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 453(2\u20133):217\u2013221","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"4_CR174","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s12035-011-8214-0","volume":"44","author":"MV Puig","year":"2011","unstructured":"Puig MV, Gulledge AT (2011) Serotonin and prefrontal cortex function: neurons, networks, and circuits. Mol Neurobiol 44(3):449\u2013464","journal-title":"Mol Neurobiol"},{"issue":"2\u20133","key":"4_CR175","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00213-010-1941-5","volume":"213","author":"H Rasmussen","year":"2011","unstructured":"Rasmussen H, Ebdrup BH, Erritzoe D, Aggernaes B, Oranje B, Kalbitzer J, Pinborg LH, Baar\u00e9 WF, Svarer C, Lublin H, Knudsen GM, Glenthoj B (2011) Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. Psychopharmacology (Berl) 213(2\u20133):583\u2013592","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"4_CR176","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)29304-6","volume":"299","author":"L Rauser","year":"2001","unstructured":"Rauser L, Savage JE, Meltzer HY, Roth BL (2001) Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther 299(1):83\u201389","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"4_CR177","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/sj.bjp.0702350","volume":"126","author":"C Reavill","year":"1999","unstructured":"Reavill C, Kettle A, Holland V, Riley G, Blackburn T (1999) Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol 126(3):572\u2013574","journal-title":"Br J Pharmacol"},{"issue":"1","key":"4_CR178","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","volume":"68","author":"E Richelson","year":"2000","unstructured":"Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68(1):29\u201339","journal-title":"Life Sci"},{"key":"4_CR179","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0079-6123(08)00908-4","volume":"172","author":"NM Richtand","year":"2008","unstructured":"Richtand NM, Welge JA, Logue AD, Keck PE Jr, Strakowski SM, McNamara RK (2008) Role of serotonin and dopamine receptor binding in antipsychotic efficacy. Prog Brain Res 172:155\u2013175","journal-title":"Prog Brain Res"},{"issue":"7","key":"4_CR180","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1021\/jm021085c","volume":"46","author":"C Riemer","year":"2003","unstructured":"Riemer C, Borroni E, Levet-Trafit B, Martin JR, Poli S, Porter RH, B\u00f6s M (2003) Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J Med Chem 46(7):1273\u20131276","journal-title":"J Med Chem"},{"key":"4_CR181","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0022-3565(25)10821-5","volume":"262","author":"M Rinaldi-Carmona","year":"1992","unstructured":"Rinaldi-Carmona M, Congy C, Santucci V, Simiand J, Gautret B, Neliat G, Labeeuw B, Le Fur G, Soubri\u00e9 PG, Breliere JC (1992) Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonists. J Pharmacol Exp Ther 262:759\u2013768","journal-title":"J Pharmacol Exp Ther"},{"key":"4_CR182","doi-asserted-by":"publisher","first-page":"R3","DOI":"10.1016\/S0014-2999(97)81951-6","volume":"338","author":"H Rollema","year":"1997","unstructured":"Rollema H, Lu Y, Schmidt AW, Zorn SH (1997) Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 338:R3\u2013R5","journal-title":"Eur J Pharmacol"},{"key":"4_CR183","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0022-3565(25)11452-3","volume":"260","author":"BL Roth","year":"1992","unstructured":"Roth BL, Ciaranello RD, Meltzer HY (1992) Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther 260:1361\u20131365","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"4_CR184","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0022-3565(25)38596-4","volume":"268","author":"BL Roth","year":"1994","unstructured":"Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268(3):1403\u20131410","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"4_CR247","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/BF02311185","volume":"120","author":"BL Roth","year":"1995","unstructured":"Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY (1995) D4 Dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl) 120(3):365\u2013368","journal-title":"Psychopharmacology (Berl)"},{"issue":"12","key":"4_CR248","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1002\/hbm.20993","volume":"31","author":"R Salvador","year":"2010","unstructured":"Salvador R, Sarr\u00f3 S, Gomar JJ, Ortiz-Gil J, Vila F, Capdevila A, Bullmore E, McKenna PJ, Pomarol-Clotet E (2010) Overall brain connectivity maps show cortico-subcortical abnormalities in schizophrenia. Hum Brain Mapp 31(12):2003\u20132014","journal-title":"Hum Brain Mapp"},{"key":"4_CR186","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/0024-3205(95)00210-W","volume":"56","author":"CJ Schmidt","year":"1995","unstructured":"Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG (1995) The role of 5-HT2A receptors in antipsychotic activity. Life Sci 56:2209\u20132222","journal-title":"Life Sci"},{"key":"4_CR187","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/BF02245606","volume":"124","author":"A Schotte","year":"1996","unstructured":"Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57\u201373","journal-title":"Psychopharmacology"},{"issue":"1\u20132","key":"4_CR188","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.neuropharm.2010.04.012","volume":"59","author":"MC Scorza","year":"2010","unstructured":"Scorza MC, Casta\u00f1\u00e9 A, Bortolozzi A, Artigas F (2010) Clozapine does not require 5-HT1A receptors to block the locomotor hyperactivity induced by MK-801 Clz and MK-801 in KO1A mice. Neuropharmacology 59(1\u20132):112\u2013120","journal-title":"Neuropharmacology"},{"issue":"1","key":"4_CR189","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.biopsych.2006.12.011","volume":"63","author":"S Semenova","year":"2008","unstructured":"Semenova S, Geyer MA, Sutcliffe JG, Markou A, Hedlund PB (2008) Inactivation of the 5-HT(7) receptor partially blocks phencyclidine-induced disruption of prepulse inhibition. Biol Psychiatry 63(1):98\u2013105","journal-title":"Biol Psychiatry"},{"issue":"1","key":"4_CR249","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/0269881107082944","volume":"23","author":"M Shahid","year":"2009","unstructured":"Shahid M, Walker GB, Zorn SH, Wong EH (2009) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 23(1):65\u201373","journal-title":"J Psychopharmacol"},{"issue":"4","key":"4_CR190","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1254\/jphs.10040SC","volume":"113","author":"EJ Shin","year":"2010","unstructured":"Shin EJ, Whang WK, Kim S, Bach JH, Kim JM, Nguyen XK, Nguyen TT, Jung BD, Yamada K, Nabeshima T, Kim HC (2010) Parishin C attenuates phencyclidine-induced schizophrenia-like psychosis in mice: involvements of 5-HT1A receptor. J Pharmacol Sci 113(4):404\u2013408","journal-title":"J Pharmacol Sci"},{"issue":"5","key":"4_CR191","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0893-133X(01)00400-6","volume":"26","author":"S Shirazi-Southall","year":"2002","unstructured":"Shirazi-Southall S, Rodriguez DE, Nomikos GG (2002) Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26(5):583\u2013594","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"4_CR192","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/BF00429548","volume":"42","author":"MT Silva","year":"1975","unstructured":"Silva MT, Calil HM (1975) Screening hallucinogenic drugs: systematic study of three behavioral tests. Psychopharmacologia 42(2):163\u2013171","journal-title":"Psychopharmacologia"},{"key":"4_CR193","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/00008877-199512000-00010","volume":"6","author":"TE Sipes","year":"1995","unstructured":"Sipes TE, Geyer MA (1995) DOI disruption of prepulse inhibition of startle in the rat is mediated by 5-HT2A and not 5-HT2C receptors. Behav Pharmacol 6:839\u2013842","journal-title":"Behav Pharmacol"},{"key":"4_CR194","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0006-8993(97)00316-8","volume":"761","author":"TE Sipes","year":"1997","unstructured":"Sipes TE, Geyer MA (1997) DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum. Brain Res 761:97\u2013104","journal-title":"Brain Res"},{"issue":"2","key":"4_CR195","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1124\/jpet.109.156349","volume":"332","author":"S Snigdha","year":"2010","unstructured":"Snigdha S, Horiguchi M, Huang M, Li Z, Shahid M, Neill JC, Meltzer HY (2010) Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 332(2):622\u2013631","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"4_CR196","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1111\/j.1460-9568.2007.05567.x","volume":"25","author":"EM Somerville","year":"2007","unstructured":"Somerville EM, Horwood JM, Lee MD, Kennett GA, Clifton PG (2007) 5-HT(2C) receptor activation inhibits appetitive and consummatory components of feeding and increases brain c-fos immunoreactivity in mice. Eur J Neurosci 25(10):3115\u20133124","journal-title":"Eur J Neurosci"},{"issue":"4","key":"4_CR197","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/FPC.0b013e328337ce3e","volume":"20","author":"RP Souza","year":"2010","unstructured":"Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL (2010) Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenet Genomics 20(4):274\u2013276","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"4_CR198","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.neuropharm.2004.04.020","volume":"47","author":"LJ Steward","year":"2004","unstructured":"Steward LJ, Kennedy MD, Morris BJ, Pratt JA (2004) The atypical antipsychotic drug clozapine enhances chronic PCP-induced regulation of prefrontal cortex 5-HT2A receptors. Neuropharmacology 47(4):527\u2013537","journal-title":"Neuropharmacology"},{"issue":"1","key":"4_CR199","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0031-6997(24)01483-2","volume":"53","author":"PG Strange","year":"2001","unstructured":"Strange PG (2001) Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 53(1):119\u2013133","journal-title":"Pharmacol Rev"},{"issue":"3","key":"4_CR200","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/00004714-200006000-00019","volume":"20","author":"T Sumiyoshi","year":"2000","unstructured":"Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Uehara T, Kurachi M, Meltzer HY (2000) Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol 20(3):386\u2013388","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"4_CR201","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1176\/appi.ajp.158.10.1722","volume":"158","author":"T Sumiyoshi","year":"2001","unstructured":"Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C, Jayathilake K, Meltzer HY (2001a) Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158(10):1722\u20131725","journal-title":"Am J Psychiatry"},{"issue":"10","key":"4_CR202","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S0006-3223(00)01025-8","volume":"49","author":"T Sumiyoshi","year":"2001","unstructured":"Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Kurachi M, Uehara T, Sumiyoshi S, Sumiyoshi C, Meltzer HY (2001b) The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry 49(10):861\u2013868","journal-title":"Biol Psychiatry"},{"key":"4_CR250","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s12325-008-0102-2","volume":"25","author":"T Sumiyoshi","year":"2008","unstructured":"Sumiyoshi T, Bubenikova-Valesova V, Horacek J, Bert B (2008) Serotonin1A Receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics. Adv Ther 25:1037\u20131056","journal-title":"Adv Ther"},{"issue":"15","key":"4_CR203","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","volume":"64","author":"T Swainston Harrison","year":"2004","unstructured":"Swainston Harrison T, Perry CM (2004) Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 64(15):1715\u20131736","journal-title":"Drugs"},{"key":"4_CR205","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1124\/jpet.102.038422","volume":"303","author":"CJ Swanson","year":"2002","unstructured":"Swanson CJ, Schoepp DD (2002) The group II metabotropic glutamate receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0]-hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats. J Pharmacol Exp Ther 303:919\u2013927","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"4_CR206","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/0306-3623(95)00077-1","volume":"26","author":"H Tanaka","year":"1995","unstructured":"Tanaka H, Tatsuno T, Shimizu H, Hirose A, Kumasaka Y, Nakamura M (1995) Effects of tandospirone on second messenger systems and neurotransmitter release in the rat brain. Gen Pharmacol 26(8):1765\u20131772","journal-title":"Gen Pharmacol"},{"issue":"12","key":"4_CR207","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.euroneuro.2009.07.005","volume":"19","author":"Y Tanibuchi","year":"2009","unstructured":"Tanibuchi Y, Fujita Y, Kohno M, Ishima T, Takatsu Y, Iyo M, Hashimoto K (2009) Effects of quetiapine on phencyclidine-induced cognitive deficits in mice: a possible role of alpha1-adrenoceptors. Eur Neuropsychopharmacol 19(12):861\u2013867","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"4_CR208","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2174\/1568007043482633","volume":"3","author":"DR Thomas","year":"2004","unstructured":"Thomas DR, Hagan JJ (2004) 5-HT7 receptors. Curr Drug Targets CNS Neurol Disord 3(1):81\u201390","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"4_CR251","first-page":"440","volume":"178","author":"L Toll","year":"1998","unstructured":"Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O\u2019Brien A, White A, Kennedy JM, Craymer K, Farrington L, Auh JS (1998) Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178:440\u2013466","journal-title":"NIDA Res Monogr"},{"issue":"6","key":"4_CR204","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00702-004-0109-z","volume":"111","author":"W Ukai","year":"2004","unstructured":"Ukai W, Ozawa H, Tateno M, Hashimoto E, Saito T (2004) Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol. J Neural Transm 111(6):667\u2013681","journal-title":"J Neural Transm"},{"issue":"4","key":"4_CR209","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00213-009-1644-y","volume":"206","author":"JM Uslaner","year":"2009","unstructured":"Uslaner JM, Smith SM, Huszar SL, Pachmerhiwala R, Hinchliffe RM, Vardigan JD, Hutson PH (2009) Combined administration of an mGlu2\/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants. Psychopharmacology (Berl) 206(4):641\u2013651","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"4_CR210","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1523\/JNEUROSCI.17-08-02785.1997","volume":"17","author":"VA Vaidya","year":"1997","unstructured":"Vaidya VA, Marek GJ, Aghajanian GK, Duman RS (1997) 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 17(8):2785\u20132795","journal-title":"J Neurosci"},{"issue":"2","key":"4_CR211","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1124\/jpet.105.097006","volume":"317","author":"KE Vanover","year":"2006","unstructured":"Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE (2006) Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N\u2032-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 317(2):910\u2013918","journal-title":"J Pharmacol Exp Ther"},{"key":"4_CR212","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0893-133X(98)00072-4","volume":"20","author":"GB Varty","year":"1999","unstructured":"Varty GB, Bakshi VP, Geyer MA (1999) M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology 20:311\u2013321","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"4_CR252","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00210-012-0734-2","volume":"385","author":"G Vauquelin","year":"2012","unstructured":"Vauquelin G, Bostoen S, Vanderheyden P, Seeman P (2012) Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch Pharmacol 385(4):337\u2013372","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"4_CR213","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1017\/S1461145710000349","volume":"14","author":"P V\u00e1zquez-Borsetti","year":"2011","unstructured":"V\u00e1zquez-Borsetti P, Celada P, Cort\u00e9s R, Artigas F (2011) Simultaneous projections from prefrontal cortex to dopaminergic and serotonergic nuclei. Int J Neuropsychopharmacol 14(3):289\u2013302","journal-title":"Int J Neuropsychopharmacol"},{"key":"4_CR253","first-page":"1","volume":"4","author":"J Volavka","year":"2012","unstructured":"Volavka J (2012) Clozapine is gold standard, but questions remain. Int J Neuropsychopharmacol 4:1\u20134","journal-title":"Int J Neuropsychopharmacol"},{"key":"4_CR254","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/7854_2010_44","volume":"4","author":"DW Volk","year":"2010","unstructured":"Volk DW, Lewis DA (2010) Prefrontal cortical circuits in schizophrenia. Curr Top Behav Neurosci 4:485\u2013508","journal-title":"Curr Top Behav Neurosci"},{"issue":"3","key":"4_CR214","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0304-3940(98)00882-9","volume":"258","author":"A Vysokanov","year":"1998","unstructured":"Vysokanov A, FloresHernandez J, Surmeier DJ (1998) mRNAs for clozapine-sensitive receptors co-localize in rat prefrontal cortex neurons. Neurosci Lett 258(3):179\u2013182","journal-title":"Neurosci Lett"},{"key":"4_CR215","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/BF01245351","volume":"89","author":"ML Wadenberg","year":"1992","unstructured":"Wadenberg ML (1992) Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. J Neural Transm Gen Sect 89:49\u201359","journal-title":"J Neural Transm Gen Sect"},{"issue":"6","key":"4_CR255","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S0006-3223(97)00424-1","volume":"44","author":"ML Wadenberg","year":"1998","unstructured":"Wadenberg ML, Hicks PB, Richter JT, Young KA (1998) Enhancement of antipsychoticlike properties of raclopride in rats using the selective serotonin2A receptor antagonist MDL 100,907. Biol Psychiatry 44(6):508\u2013515","journal-title":"Biol Psychiatry"},{"issue":"2","key":"4_CR216","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.npp.1300626","volume":"30","author":"M Wagner","year":"2005","unstructured":"Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, K\u00fchn KU (2005) Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology 30(2):381\u2013390","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"4_CR217","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.bcp.2011.06.034","volume":"82","author":"TL Wallace","year":"2011","unstructured":"Wallace TL, Porter RH (2011) Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease. Biochem Pharmacol 82(8):891\u2013903","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"4_CR219","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0893-133X(98)00003-7","volume":"19","author":"RY Wang","year":"1995","unstructured":"Wang RY, Liang X (1995) M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology 19(1):74\u201385","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"4_CR220","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.biopsych.2008.08.007","volume":"64","author":"L Wang","year":"2008","unstructured":"Wang L, Mamah D, Harms MP, Karnik M, Price JL, Gado MH, Thompson PA, Barch DM, Miller MI, Csernansky JG (2008) Progressive deformation of deep brain nuclei and hippocampal-amygdala formation in schizophrenia. Biol Psychiatry 64(12):1060\u20131068","journal-title":"Biol Psychiatry"},{"issue":"4","key":"4_CR221","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/0306-4522(94)00439-C","volume":"64","author":"RP Ward","year":"1995","unstructured":"Ward RP, Hamblin MW, Lachowicz JE, Hoffman BJ, Sibley DR, Dorsa DM (1995) Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience 64(4):1105\u20131111","journal-title":"Neuroscience"},{"issue":"1","key":"4_CR222","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bbr.2011.12.009","volume":"228","author":"KA Waters","year":"2011","unstructured":"Waters KA, Stean TO, Hammond B, Virley DJ, Upton N, Kew JN, Hussain I (2011) Effects of the selective 5-HT(7) receptor antagonist SB-269970 in animal models of psychosis and cognition. Behav Brain Res 228(1):211\u2013218","journal-title":"Behav Brain Res"},{"issue":"4","key":"4_CR223","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1017\/S1461145711000435","volume":"15","author":"DJ Watson","year":"2012","unstructured":"Watson DJ, Marsden CA, Millan MJ, Fone KC (2012) (2 012). Blockade of dopamine D3 but not D2 receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment. Int J Neuropsychopharmacol 15(4):471\u2013484","journal-title":"Int J Neuropsychopharmacol"},{"key":"4_CR224","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0022-3565(24)29327-7","volume":"299","author":"DM Weiner","year":"2001","unstructured":"Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohue E, Hansen HC, Andersson CM, Spalding TA, Gibson DF, Krebs-Thomson K, Powell SB, Geyer MA, Hacksell U, Brann MR (2001) 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 299:268\u2013276","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"4_CR225","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF02245441","volume":"114","author":"FA Wiesel","year":"1994","unstructured":"Wiesel FA, Nordstr\u00f6m AL, Farde L, Eriksson B (1994) An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology (Berl) 114(1):31\u201338","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"4_CR226","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0022-3565(24)36840-5","volume":"282","author":"DL Willins","year":"1997","unstructured":"Willins DL, Meltzer HY (1997) Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther 282(2):699\u2013706","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"4_CR227","doi-asserted-by":"crossref","first-page":"37","DOI":"10.31887\/DCNS.2006.8.1\/bwinklbaur","volume":"8","author":"B Winklbaur","year":"2006","unstructured":"Winklbaur B, Ebner N, Sachs G, Thau K, Fischer G (2006) Substance abuse in patients with schizophrenia. Dialogues Clin Neurosci 8(1):37\u201343","journal-title":"Dialogues Clin Neurosci"},{"issue":"3","key":"4_CR228","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1017\/S146114570500516X","volume":"8","author":"ND Woodward","year":"2005","unstructured":"Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8(3):457\u2013472","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"4_CR229","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1124\/jpet.111.183780","volume":"339","author":"PN Yadav","year":"2011","unstructured":"Yadav PN, Kroeze WK, Farrell MS, Roth BL (2011) Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. J Pharmacol Exp Ther 339(1):99\u2013105","journal-title":"J Pharmacol Exp Ther"},{"key":"4_CR256","first-page":"1","volume":"10","author":"N Yamasaki","year":"2008","unstructured":"Yamasaki N, Maekawa M, Kobayashi K, Kajii Y, Maeda J, Soma M, Takao K, Tanda K, Ohira K, Toyama K, Kanzaki K, Fukunaga K, Sudo Y, Ichinose H, Ikeda M, Iwata N, Ozaki N, Suzuki H, Higuchi M, Suhara T, Yuasa S, Miyakawa T (2008) Alpha-CaMKII deficiency causes immature dentate gyrus, a novel candidate endophenotype of psychiatric disorders. Mol Brain 10:1\u20136","journal-title":"Mol Brain"},{"issue":"2","key":"4_CR230","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/jpet.108.143461","volume":"327","author":"B Yu","year":"2008","unstructured":"Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, Nichols CD (2008) Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency. J Pharmacol Exp Ther 327(2):316\u2013323","journal-title":"J Pharmacol Exp Ther"},{"issue":"25","key":"4_CR231","doi-asserted-by":"publisher","first-page":"17194","DOI":"10.1074\/jbc.M801713200","volume":"283","author":"EY Yuen","year":"2008","unstructured":"Yuen EY, Jiang Q, Chen P, Feng J, Yan Z (2008) Activation of 5-HT2A\/C receptors counteracts 5-HT1A regulation of n-methyl-D-aspartate receptor channels in pyramidal neurons of prefrontal cortex. J Biol Chem 283(25):17194\u201317204","journal-title":"J Biol Chem"},{"issue":"23","key":"4_CR232","doi-asserted-by":"publisher","first-page":"5488","DOI":"10.1523\/JNEUROSCI.1187-05.2005","volume":"25","author":"EY Yuen","year":"2005","unstructured":"Yuen EY, Jiang Q, Chen P, Gu Z, Feng J, Yan Z (2005) Serotonin 5-HT1A receptors regulate NMDA receptor channels through a microtubule-dependent mechanism. J Neurosci 25(23):5488\u20135501","journal-title":"J Neurosci"},{"issue":"2","key":"4_CR233","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1124\/mol.111.076141","volume":"81","author":"EY Yuen","year":"2012","unstructured":"Yuen EY, Li X, Wei J, Horiguchi M, Meltzer HY, Yan Z (2012) The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses. Mol Pharmacol 81(2):113\u2013119","journal-title":"Mol Pharmacol"},{"issue":"4","key":"4_CR234","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.bmc.2011.12.039","volume":"20","author":"P Zajdel","year":"2012","unstructured":"Zajdel P, Marciniec K, Ma\u015blankiewicz A, Sata\u0142a G, Duszy\u0144ska B, Bojarski AJ, Partyka A, Jastrz\u0119bska-Wi\u0119sek M, Wr\u00f3bel D, Weso\u0142owska A, Paw\u0142owski M (2012) Quinoline- and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor-5-HT1A\/5-HT2A\/5-HT7 and D2\/D3\/D4-agents: the synthesis and pharmacological evaluation. Bioorg Med Chem 20(4):1545\u20131556","journal-title":"Bioorg Med Chem"},{"issue":"4","key":"4_CR235","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.bcp.2005.11.007","volume":"71","author":"JY Zhang","year":"2006","unstructured":"Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J (2006) Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol 71(4):521\u2013529","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"4_CR236","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00213-004-1975-7","volume":"178","author":"XY Zhang","year":"2005","unstructured":"Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC (2005) Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study. Psychopharmacology (Berl) 178(1):35\u201340","journal-title":"Psychopharmacology (Berl)"}],"container-title":["Handbook of Experimental Pharmacology","Current Antipsychotics"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-25761-2_4.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T07:14:18Z","timestamp":1745133258000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-642-25761-2_4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"ISBN":["9783642257605","9783642257612"],"references-count":245,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-25761-2_4","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}